Επειδή σε καποιες συζητησεις στο φόρουμ διαβλέπω ενα θαυμασμό για το νέο, θαυματουργό αντιπηκτικό, που δεν χρειάζεται μάλιστα έλεγχο της δρασης του, όπως το Sintrom, και επειδή διαπιστώνω οτι στην περιοχή μας οι καρδιολόγοι εχουν αρχισει να το υπερ-συνταγογραφούν, ως τάχα στερούμενο παρενεργειών, αναδημοσιεύω ενα Δεν είναι ορατοί οι σύνδεσμοι (links).
Εγγραφή ή
Είσοδοςαπο το Medscape News για θανατηφόρα εγκεφαλική αιμορραγία ηλικιωμενου ασθενους, μετα απο ήσσονος βαρύτητας χτύπημα στο κεφάλι.
Death After Routine Fall Magnifies Pradaxa Hemorrhage Concerns Mar 08, 2012
By Ransdell Pierson
(Reuters) Mar 07 - The death of an elderly man from a massive brain hemorrhage after a routine fall suggests that bleeding complications from Boehringer Ingelheim's Pradaxa (dabigatran) are largely irreversible, according to the Journal of Neurosurgery.
The recently approved drug is the first in a new class of oral medicines called direct thrombin inhibitors, approved to prevent strokes among patients with atrial fibrillation.
U.S. regulators in December said they were evaluating other cases of bleeding associated with the drug but advised patients to continue the medicine for now.
Three doctors from the University of Utah monitored and described the worsening condition, and ultimate death, of the 83-year-old man who was evaluated at their medical center for what seemed at first a rather routine fall, according to the report today in the journal's online edition.
Initially, the patient was fully alert and oriented and could respond to verbal commands, and his neurological exam produced no findings of great concern, the clinicians said.
They said CT scans revealed small, superficial areas of hemorrhage in his brain, but that within two hours after arriving at the hospital new scans showed extensive progression of brain hemorrhaging.
Efforts to stop the hemorrhaging, including intravenous fluids and recombinant factor VIIa, proved ineffective and the patient fell into a deep coma and died soon afterward, the report said.
"In the event of traumatic hemorrhage in patients receiving dabigatran ... there are currently no effective reversal agents" to neutralize the drug, the report said.
Familiarity with Pradaxa is critical in order for medical personnel to take quick action with admittedly limited available means to control catastrophic bleeding, the report said.
Researchers speculated that dialysis might remove 35% to 60% of Pradaxa from the bloodstream in two to three hours, but noted that option was not taken with the elderly patient. "By the time of his deterioration it was too late to implement effectively."
Since balance problems and falls are common for elderly patients, cases of brain hemorrhage even from a minor trauma are likely to increase as more patients get prescribed Pradaxa, the researchers said.
Pradaxa was approved by U.S. regulators in October 2010 for stroke prevention in patients with atrial fibrillation. It is the first of a new group of blood clot preventers meant to replace warfarin, which itself carries serious bleeding risks and requires routine blood monitoring and stringent dietary restrictions.
The report said patients taking the highest dose of Pradaxa in a large clinical trial sponsored by Boehringer had a similar overall rate of brain hemorrhage as those taking warfarin, while having a lower annual incidence of stroke. But the lack of a reversal agent in the event of catastrophic hemorrhage remains a handicap, they said.
The new medicine from privately held German drugmaker Boehringer Ingelheim competes with Xarelto (rivaroxaban), a pill from Johnson & Johnson and Bayer AG, approved four months ago in the United States that works by blocking Factor Xa.
Another Factor Xa inhibitor from Bristol-Myers Squibb Co and Pfizer Inc, called Eliquis (apixaban), is being reviewed by the U.S. Food and Drug Administration for approval.
J Neurosurg 2012.
Θέμα: Δαβιγατράνη ( Pradaxa ). (Αναγνώστηκε 205023 φορές)
2 Ιουλίου 2017, 00:54:26